Plain-English translation of NCT05854498 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether three medications used together — , , and — can help people with advanced colorectal cancer whose disease has continued to grow despite previous treatment. The research team wants to see how long people survive without their cancer getting worse, and whether the medication combination causes manageable side effects.
People with advanced colorectal cancer that has already been treated with multiple standard chemotherapy drugs often have very few options left. This trial exists to see whether combining these three medications in a new way might help patients whose cancer has stopped responding to earlier treatments.
You likely qualify if…
You likely don't qualify if…
You would visit the University of Wisconsin Carbone Cancer Center regularly to receive the three medications as part of your cancer treatment. The trial expects to enroll about 25 patients over 12 months, and the entire study will last about 3 years. Your doctors will monitor how well the medication works, watch for side effects, and track how long your cancer stays stable or shrinks.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Wisconsin, Madison
Collaborators
Ipsen
Enrollment target
~50 participants
Started
October 2023
Primary completion
July 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cancer Connect
UW Carbone Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.